News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orexo AB Announces Full Implementation of Its ADR Program in the United States Concurrently With Its Commercial Launch of Zubsolv®


9/16/2013 9:22:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Uppsala, Sweden – September 16, 2013 – Orexo AB (STO: ORX) announced today that a sponsored level 1 American Depositary Receipt (ADR) program in the United States has now been fully implemented and the ADRs can now be traded on the OTC market under the symbol ORXOY. Implementation of the ADR program coincides with the commercial launch of Zubsolv®, which is the company’s leading product for maintenance treatment of opioid dependence.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Orexo AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES